Caribou Biosciences (CRBU) Non-Current Deffered Revenue (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue fell 37.12% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 37.12% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 47.18% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $1.6 million, down from $1.8 million in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for CRBU reached as high as $18.2 million in Q2 2023 and fell as low as $1.6 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $6.9 million across 5 years, with a median of $4.6 million in 2024.
• Across the five-year window, Non-Current Deffered Revenue surged 741.41% in 2022 and plunged 74.65% in 2024, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $16.0 million in 2022, then slumped by 61.75% to $6.1 million in 2023, then slumped by 45.64% to $3.3 million in 2024, then plunged by 47.18% to $1.8 million in 2025, then retreated by 5.94% to $1.6 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $1.6 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.